[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"drug-craving\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:drug-craving":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":45,"leadSponsor":47,"locationsCount":5},"100646528","the-efficacy-of-transcutaneous-auricular-vagus-nerve-stimulation-in-individuals-with-tiletamine-use-disorder-100646528",false,"NCT07689981","The Efficacy of Transcutaneous Auricular Vagus Nerve Stimulation in Individuals With Tiletamine Use Disorder","Effect of Transcutaneous Auricular Vagus Nerve Stimulation on Patients With Tiletamine Use Disorder: A Randomized Double-Blind Sham-Controlled Trial","taVNS-Tiletami","Inclusion Criteria:\n\n* Age 18-60 years ≥6 years of education\\[7.1\\] DSM-5 diagnosis of substance use disorder related to tiletamine Tiletamine use ≥6 months and ≥1 time\u002Fweek Ability to provide informed consent Willingness to complete follow-up assessments\n\nExclusion Criteria:\n\n* Severe cognitive impairment History of epilepsy, brain injury, neurological disease or serious psychiatric disease Use of cognition-enhancing medications within 6 months Other psychoactive substance abuse within past 5 years (except nicotine) Metal implants in the head or severe skin sensitivity","ALL","18 Years","60 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"NA","Participants diagnosed with tiletamine use disorder will be assigned to active or sham taVNS for 5 days. Clinical outcomes ( e.g., behavioral paradigms measures and clinical scales ) and physiological markers (e.g., EEG and ECG) will be evaluated at baseline, post-treatment, and 3-month follow-ups to determine therapeutic efficacy and mechanisms of action.",[28,29,30],"Tiletamine Use Disorder","Substance Use Disorder (SUD)","Drug Craving",[32,33,34,35,36,37,30,38],"taVNS","Addiction","Brain-Heart Coupling","HRV","EEG","Neuromodulation","Tiletamine Dependence","NOT_YET_RECRUITING","2026-07-01",{"date":42,"type":43},"2026-07-08","ACTUAL",{"date":40,"type":22},{"date":46,"type":22},"2028-01-01",{"name":48,"class":49},"Shanghai Mental Health Center","OTHER"]